Sandford Smith, Director at Aegerion, holds 18.65K shares in Cytokinetics (Ticker: CYTK), holds 219.92K shares in Palisade Bio (Ticker: PALI), holds ― shares in Novelion Therapeutics (Ticker: NVLNF).
Sandford Smith latest transaction was an Uninformative Buy of $12.49K.
What was Sandford Smith's most profitable transaction?
Sandford Smith’s most profitable transaction was an Informative Sell of CYTK stock on September 2, 2022. The return on the trade was 33.40%.
What is Sandford Smith's role in Aegerion?
Sandford Smith's role in Aegerion is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.